Zobrazeno 1 - 10
of 28
pro vyhledávání: '"R T Woolf"'
Autor:
A D Burden, Martinsixtus C. Ezejimofor, R Parslew, Z.Z.N. Yiu, R T Woolf, L S Exton, Satveer K. Mahil, Ruth Murphy, Catherine H. Smith, M F Mohd Mustapa, C. M. Owen, L Manounah
BackgroundThe increase in the number of available biologic agents for psoriasis has led to an urgent need to evaluate their associated risk of serious infections to help inform clinical decisions.MethodologyWe systematically searched PubMed, Medline,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e828e611e1f87ce3ce8294db8acdce8
https://doi.org/10.1101/2021.08.27.21262722
https://doi.org/10.1101/2021.08.27.21262722
Autor:
Catherine H. Smith, W Abdelrahman, E Gribaleva, Andrew Pink, A V Sears, Bruce Kirkham, Bina Menon, S Robbie, R T Woolf
Publikováno v:
The British journal of dermatologyReferences. 184(4)
Autor:
Catherine H. Smith, R Parslew, M F Mohd Mustapa, A D Burden, Zenas Z N Yiu, C. M. Owen, Martinsixtus C. Ezejimofor, Laura C Coates, L Manounah, Satveer K. Mahil, Ruth Murphy, L S Exton, A McGuire, M de Brito, Olalekan A. Uthman, R T Woolf
Publikováno v:
Mahil, S K, Ezejimofor, M C, Exton, L S, Manounah, L, Burden, A D, Coates, L C, de Brito, M, McGuire, A, Murphy, R, Owen, C M, Parslew, R, Woolf, R T, Yiu, Z Z N, Uthman, O A, Mohd Mustapa, M F & Smith, C H 2020, ' Comparing the efficacy and tolerability of biologic therapies in psoriasis : an updated network meta-analysis ', The British journal of dermatology . https://doi.org/10.1111/bjd.19325
Background The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform treatment decisions better and, specifically, to inform guideline development. Objectives To update a 201
Autor:
Zena Willsmore, Bina Menon, Catherine H. Smith, R T Woolf, Andrew Pink, Catherine D Hughes, Bruce Kirkham
Publikováno v:
Rheumatology. 59
Background Dupilumab is a recombinant human monoclonal antibody that inhibits signalling of interleukin-4 and interleukin-13. It has NICE approval for use in patients with moderate to severe atopic eczema who have failed at least one standard therapy
Publikováno v:
Clinical and Experimental Dermatology. 45:232-234
Autor:
Julie Owen, Cristina Naceur-Lombardelli, Fernanda Kyle-Cezar, Adrian Hayday, Anita Grigoriadis, Pierre Vantourout, Andrew Tutt, Dhruva Biswas, Patrycja Gazinska, Yin Wu, R T Woolf, Anna Lorenc
Publikováno v:
Science Translational Medicine. 11
Innate-like tissue-resident γδ T cell compartments capable of protecting against carcinogenesis are well established in mice. Conversely, the degree to which they exist in humans, their potential properties, and their contributions to host benefit
Publikováno v:
The British journal of dermatology. 180(3)
Background Atopic dermatitis is the most common chronic inflammatory skin disorder, affecting up to 20% of children and 10% of adults in industrialized countries. This highly debilitating condition poses a considerable burden to both the individual a
Publikováno v:
British Journal of Dermatology. 181:385-386
Autor:
E.M. Pottinger, Catherine H. Smith, R T Woolf, Catherine Nelson-Piercy, L S Exton, A D Burden
Publikováno v:
The British journal of dermatology. 178(1)
SummaryBackground Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. Objectives To evaluate the safety of biological therapy in conception and/or pregnancy. Methods We performed a syste
Autor:
A. M. Peters van Ton, Cathryn M. Lewis, Anthony M. Marinaki, M. Arenas-Hernandez, Sarah Spain West, Catherine H. Smith, Naomi Hare, Jonathan Barker, R T Woolf
Publikováno v:
British Journal of Dermatology. 167:165-173
BACKGROUND Methotrexate is activated by the sequential addition of glutamic acid residues to form methotrexate polyglutamates (MTXPG(1-5)). MTXPG(1-5) inhibit enzymes of the folate-purine-pyrimidine pathways, and longer-chain MTXPG(3-5) species are m